Joanne de Hullu

Joanne de Hullu

Auto-generated profile, based on publicly available information

Joanne de Hullu

Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MHMarline G. Harmsen
Marline G. Harmsen
MJMarieke Arts-De Jong
Marieke Arts-De Jong
NHNicoline Hoogerbrugge
Nicoline Hoogerbrugge
AMAngela H. E. M. Maas
Angela H. E. M. Maas
JPJudith B. Prins
Judith B. Prins
JHJoanne A. de Hullu
Joanne A. de Hullu
Risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 is currently recommended to BRCA1/2 mutation carriers. This procedure decreases the elevated ovarian cancer risk by 80–96 % but it initiates premature menopause as well. The latter is associated with short-term and long-term morbidity, potentially affecting quality of life (QoL). Based on recent insights into the Fallopian tube as possible site of origin of serous ovarian carcinomas, an alternative preventive strategy has been put forward: early risk-reducing salpingectomy (RRS) and delayed oophorectomy (RRO). However, efficacy and safety of this alternative strategy have to be investigated. A multicentre non-randomised trial in 11 Dutch centres for hereditary cancer will be conducted. Eligible patients are premenopausal BRCA1/2 mutation carriers after completing childbearing without (a history of) ovarian carcinoma. Participants choose between standard RRSO at age 35–40 (BRCA1) or 40–45 (BRCA2) and the alternative strategy (RRS upon completion of childbearing and RRO at age 40–45 (BRCA1) or 45–50 (BRCA2)). Women who opt for RRS but do not want to postpone RRO beyond the currently recommended age are included as well. Primary outcome measure is menopause-related QoL. Secondary outcome measures are ovarian/breast cancer incidence, surgery-related morbidity, histopathology, cardiovascular risk factors and diseases, and cost-effectiveness. Mixed model data analysis will be performed. The exact role of the Fallopian tube in ovarian carcinogenesis is still unclear. It is not expected that further fundamental research will elucidate this role in the near future. Therefore, this clinical trial is essential to investigate RRS with delayed RRO as alternative risk-reducing strategy in order to improve QoL. ClinicalTrials.gov ( NCT02321228 )

3 June 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MSMiranda P. Steenbeek
Miranda P. Steenbeek
MHMarline G. Harmsen
Marline G. Harmsen
NHNicoline Hoogerbrugge
Nicoline Hoogerbrugge
MJMarieke Arts de Jong
Marieke Arts de Jong
AMAngela H. E. M. Maas
Angela H. E. M. Maas
JHJoanne A. de Hullu
Joanne A. de Hullu
Cancer of the ovaries, fallopian tubes, and peritoneum is the most lethal type of gynecologic cancer. Women with a pathogenic variant (PV) in a BRCA1/2 gene have a lifetime risk of ovarian cancer of about 44% (BRCA1) or 17% (BRCA2).1 No effective screening is currently available.2 Therefore, these women are advised to undergo risk-reducing salpingo-oophorectomy (RRSO) at the age of 35 to 40 years (BRCA1-PV) or 40 to 45 years (BRCA2-PV), before incidences rise.3

11 May 2019 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JVJanet Vos
Janet Vos
IFIngrid E Fakkert
Ingrid E Fakkert
JHJoanne A de Hullu
Joanne A de Hullu
AAAnne M van Altena
Anne M van Altena
ASAisha S Sie
Aisha S Sie
RARiena P Aliredjo
Riena P Aliredjo
Women with epithelial ovarian cancer (OC) have a higher chance to benefit from poly (ADP-ribose) polymerase inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant. Current guidelines advise BRCA1/2 genetic predisposition testing for all OC patients, though this does not detect somatic variants. We assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as a prescreen for PARPi treatment and cancer predisposition testing. Formalin-fixed paraffin-embedded tissue was obtained from OC patients in seven hospitals immediately after diagnosis or primary surgery. DNA was extracted, and universal tumor BRCA1/2 testing was then performed in a single site. Diagnostic yield, uptake, referral rates for genetic predisposition testing, and experiences of patients and gynecologists were evaluated. Tumor BRCA1/2 testing was performed for 315 (77.6%) of the 406 eligible OC samples, of which 305 (96.8%) were successful. In 51 of these patients, pathogenic variants were detected (16.7%). Most patients (88.2%) went on to have a genetic predisposition test. BRCA1/2 pathogenic variants were shown to be hereditary in 56.8% and somatic in 43.2% of patients. Participating gynecologists and patients were overwhelmingly positive about the workflow. Universal tumor BRCA1/2 testing in all newly diagnosed OC patients is feasible, effective, and appreciated by patients and gynecologists. Because many variants cannot be detected in DNA from blood, testing tumor DNA as the first step can double the identification rate of patients who stand to benefit most from PARP inhibitors.

12 April 2023 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
MSMiranda Steenbeek
Miranda Steenbeek
MBMajke H D van Bommel
Majke H D van Bommel
JIJoanna Inthout
Joanna Inthout
CPChristine B Peterson
Christine B Peterson
MSMichiel Simons
Michiel Simons
JHJoanne A de Hullu
Joanne A de Hullu
Background Risk-reducing salpingectomy with delayed oophorectomy has gained interest for individuals at high risk for tubo-ovarian cancer as there is compelling evidence that especially high-grade serous carcinoma originates in the fallopian tubes. Two studies have demonstrated a positive effect of salpingectomy on menopause-related quality of life and sexual health compared with standard risk-reducing salpingo-oophorectomy. Primary Objective To investigate whether salpingectomy with delayed oophorectomy is non-inferior to the current standard salpingo-oophorectomy for the prevention of tubo-ovarian cancer among individuals at high inherited risk. Study Hypothesis We hypothesize that postponement of oophorectomy after salpingectomy, to the age of 40–45 (BRCA1) or 45–50 (BRCA2) years, compared with the current standard salpingo-oophorectomy at age 35–40 (BRCA1) or 40–45 (BRCA2) years, is non-inferior in regard to tubo-ovarian cancer risk. Trial Design In this international prospective preference trial, participants will choose between the novel salpingectomy with delayed oophorectomy and the current standard salpingo-oophorectomy. Salpingectomy can be performed after the completion of childbearing and between the age of 25 and 40 (BRCA1), 25 and 45 (BRCA2), or 25 and 50 (BRIP1, RAD51C, and RAD51D pathogenic variant carriers) years. Subsequent oophorectomy is recommended at a maximum delay of 5 years beyond the upper limit of the current guideline age for salpingo-oophorectomy. The current National Comprehensive Cancer Network (NCCN) guideline age, which is also the recommended age for salpingo-oophorectomy within the study, is 35–40 years for BRCA1, 40–45 years for BRCA2, and 45–50 years for BRIP1, RAD51C, and RAD51D pathogenic variant carriers. Major Inclusion/Exclusion Criteria Premenopausal individuals with a documented class IV or V germline pathogenic variant in the BRCA1, BRCA2, BRIP1, RAD51C, or RAD51D gene who have completed childbearing are eligible for participation. Participants may have a personal history of a non-ovarian malignancy. Primary Endpoint The primary outcome is the cumulative tubo-ovarian cancer incidence at the target age: 46 years for BRCA1 and 51 years for BRCA2 pathogenic variant carriers. Sample size The sample size to ensure sufficient power to test non-inferiority of salpingectomy with delayed oophorectomy compared with salpingo-oophorectomy requires 1500 BRCA1 and 1500 BRCA2 pathogenic variant carriers. Estimated Dates for Completing Accrual and Presenting Results Participant recruitment is expected to be completed at the end of 2026 (total recruitment period of 5 years). The primary outcome is expected to be available in 2036 (minimal follow-up period of 10 years). Trial Registration Number NCT04294927.

1 March 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
LDLena van Doorn
Lena van Doorn
HBHeleen J. Van Beekhuizen
Heleen J. Van Beekhuizen
KGKatja Gaarenstroom
Katja Gaarenstroom
JVJacobus van der Velden
Jacobus van der Velden
AZAte G.J. van der Zee
Ate G.J. van der Zee
JHJohanna A. de Hullu
Johanna A. de Hullu

6 September 2017 in JMIR Research Protocols
Verified
Journal Article
Open access
MLMichelle van der Linden
Michelle van der Linden
KMKim Meeuwis
Kim Meeuwis
CHColette van Hees
Colette van Hees
EDEleonora van Dorst
Eleonora van Dorst
JBJohan Bulten
Johan Bulten
JHJoanne de Hullu
Joanne de Hullu
Vulvar Paget disease is a rare skin disorder, which is most common in postmenopausal Caucasian women. They usually present with an erythematous plaque that may show fine or typical "cake icing" scaling or ulceration that may cause itching, pain, irritation, or a burning sensation. Although most cases are noninvasive, vulvar Paget disease may be invasive or associated with an underlying vulvar or distant adenocarcinoma. The histological evidence of so-called "Paget cells" with abundant pale cytoplasm in the epithelium confirms the diagnosis. The origin of these Paget cells is still unclear. Treatment of choice is wide local excision with negative margins. Obtaining clear surgical margins is challenging and may lead to extensive and mutilating surgery. Even then, recurrence rates are high, ranging from 15% to 70%, which emphasizes the need for new treatment options. A number of case reports, retrospective case series, and one observational study have shown promising results using the topical immune response modifier imiquimod. This study aims to investigate the efficacy, safety, and immunological response in patients with noninvasive vulvar Paget disease using a standardized treatment schedule with 5% imiquimod cream. Topical 5% imiquimod cream might be an effective and safe treatment alternative for vulvar Paget disease. The Paget Trial is a multicenter observational cohort study including eight tertiary referral hospitals in the Netherlands. It is ethically approved by the Medical-Ethical Committee of Arnhem-Nijmegen and registered in the Central Committee on Research Involving Human Subjects (CCMO) Register by as NL51648.091.14. Twenty patients with (recurrent) noninvasive vulvar Paget disease will be treated with topical 5% imiquimod cream three times a week for 16 weeks. The primary efficacy outcome is the reduction in lesion size at 12 weeks after end of treatment. Secondary outcomes are safety, immunological response, and quality of life. Safety will be assessed by evaluation of adverse events and tolerability of treatment. To evaluate the immunological response, various immunological markers will be tested on biopsy specimens taken before, during, and after treatment. Quality of life will be assessed with three questionnaires taken before, during, and after treatment. First results are expected in the summer of 2018. ClinicalTrials.gov NCT02385188; https://clinicaltrials.gov/ct2/show/NCT02385188 (Archived by WebCite at http://www.webcitation.org/6sXygHuhP).